In an 82-year-old man with benign prostatic hyperplasia on dutasteride, can cefuroxime be combined with fosfomycin for treatment of a complicated urinary tract infection?

Can Cefuroxime and Fosfomycin Be Combined for Complicated UTI in an 82-Year-Old Man with BPH?

Yes, cefuroxime (a second-generation cephalosporin) and fosfomycin can be combined for treating complicated UTI in this patient, as this combination aligns with current guideline-recommended regimens for complicated UTIs with systemic symptoms.

Guideline-Based Rationale for Combination Therapy

The 2024 European Association of Urology guidelines provide strong recommendations for combination therapy in complicated UTIs, specifically endorsing a second-generation cephalosporin plus an aminoglycoside as empirical treatment 1. While fosfomycin is not an aminoglycoside, the principle of combination therapy for complicated UTIs is well-established in these guidelines 1.

Why This Patient Has a Complicated UTI

This 82-year-old man meets multiple criteria for complicated UTI 1:

• Male sex (all UTIs in males are considered complicated) 1
• Benign prostatic hyperplasia causing potential obstruction and incomplete voiding 1
• Age-related factors increasing risk of multidrug-resistant organisms 1

Treatment duration should be 14 days in men when prostatitis cannot be excluded 1, which is highly relevant given his BPH and the anatomical proximity of infection.

Evidence Supporting Each Agent

Cefuroxime for Complicated UTI

Cefuroxime is FDA-approved for urinary tract infections caused by E. coli and Klebsiella species 2. Historical data demonstrates equal efficacy to other cephalosporins in complicated UTIs, with 97% negative urine cultures one day after treatment and 62% cure rates one week post-treatment 3.

Fosfomycin for Complicated UTI

High-certainty evidence from two randomized controlled trials (ZEUS and FOREST) supports intravenous fosfomycin for complicated UTIs 4:

• The FOREST trial specifically included bacteremic complicated UTIs caused by E. coli 4
• No significant differences in clinical or microbiological cure compared to meropenem or piperacillin-tazobactam 4
• Effective against cephalosporin-resistant and ESBL-producing Enterobacterales 4

Critical safety caveat: In the FOREST trial, 8.6% of patients receiving IV fosfomycin developed heart failure compared to 1.4% with meropenem 4. Assess cardiac risk factors before using fosfomycin in this 82-year-old patient 4.

Fosfomycin's Specific Advantage in BPH/Prostatitis

Fosfomycin has excellent prostatic tissue penetration, making it particularly valuable when prostatitis cannot be excluded 5, 6. In chronic bacterial prostatitis studies, fosfomycin achieved 73% clinical cure and 78% microbiological cure rates 6. This is especially relevant given that 14-day treatment is recommended for men when prostatitis cannot be excluded 1.

Practical Treatment Algorithm

Initial Assessment

• Obtain urine culture and susceptibility testing immediately 1
• Assess severity: Check for systemic symptoms (fever, rigors, altered mental status) 1
• Evaluate cardiac risk before fosfomycin use (history of heart failure, ejection fraction) 4
• Consider imaging of upper urinary tract to identify underlying abnormalities 7

Empirical Combination Therapy

If systemically ill with fever/sepsis:

• Cefuroxime IV (standard dosing per FDA label) 2
• Plus fosfomycin IV (if no cardiac contraindications) 4
• This provides broad coverage while awaiting culture results 1

Tailoring Based on Culture Results

• Adjust antibiotics based on susceptibility testing 1
• Consider oral step-down therapy after 48 hours afebrile and hemodynamically stable 1
• Complete 14 days total given male sex and BPH (prostatitis cannot be excluded) 1

Important Caveats and Pitfalls

Fosfomycin Cardiac Risk

The most critical pitfall is fosfomycin-associated heart failure 4. In an 82-year-old patient:

• Screen for pre-existing cardiac disease
• Monitor fluid status closely during IV fosfomycin
• Consider alternative combinations if significant cardiac history exists

Aminoglycoside Alternative

The guidelines actually recommend second-generation cephalosporin plus aminoglycoside as the standard combination 1. If fosfomycin is contraindicated:

• Cefuroxime plus gentamicin would be the guideline-concordant choice 1
• Limit aminoglycoside duration to ≤7 days to minimize nephrotoxicity risk 4

BPH Management

Address the underlying urological abnormality 1:

• Continue dutasteride for BPH management 8, 9
• Consider urology referral if recurrent infections occur 7
• Recurrent or persistent UTI in men with BPH is an indication for surgical treatment 7

Resistance Considerations

The microbial spectrum in complicated UTIs is broader, with higher rates of antimicrobial resistance including ESBL-producing organisms 1. This patient population commonly harbors E. coli, Proteus, Klebsiella, Pseudomonas, Serratia, and Enterococcus species 1.

Do not use fluoroquinolones empirically if the patient is from a urology department or has used fluoroquinolones in the last 6 months 1.